Anemia
News
Drug elicits responses in MDS patients
VALENCIA, SPAIN—Phase 2 results suggest luspatercept can produce erythroid responses and enable transfusion independence in patients with...
News
Novel inhibitor proves ‘potent’ in hematologic malignancies
BOSTON—A pair of preclinical studies suggest the FLT3/BTK inhibitor CG’806 is active in a range of hematologic malignancies. In one of the...
News
Study shows similar outcomes with RIC and MAC in MDS
Results of a phase 3 trial revealed similar outcomes in patients who underwent allogeneic hematopoietic stem cell transplant (HSCT) to treat...
Conference Coverage
In sickle cell disease, osteomyelitis is a tough call
MONTREAL – How could ESR change osteomyelitis diagnosis in patients with SCD?
From the Journals
FDA boxed warning leads to drop off in use of ESAs
The FDA warning language was linked with a sharp decrease in use of erythropoietin-stimulating agents in colorectal, breast, and lung cancer...
News
Role of TET2 in hematologic malignancies
New research appears to explain how TET2 mutations increase the risk of hematologic malignancies. In studying mouse models and patient samples,...
From the Journals
Eltrombopag improves frequency, speed, robustness of hematologic recovery
Adding eltrombopag to standard immunosuppressive therapy markedly improved the hematologic recovery in patients with severe aplastic anemia.
News
Combo improves response rates in treatment-naïve SAA
Adding eltrombopag to immunosuppressive therapy (IST) can produce high rates of response in treatment-naïve severe aplastic anemia (SAA),...
News
FDA: REMS no longer necessary for epoetin, darbepoetin
The REMS program was put in place to make sure that the benefits of erythropoiesis-stimulating agents outweighed the risks when prescribed.
News
FDA: REMS for ESAs no longer needed, though risks persist
The US Food and Drug Administration (FDA) has determined that the risk evaluation and mitigation strategy (REMS) for erythropoiesis-stimulating...
News
Study supports use of tPA in stroke patients with SCD
A new study suggests that having sickle cell disease (SCD) should not prevent patients from receiving tissue plasminogen activator (tPA) to treat...